Ewopharma
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Adenosine A3 receptor | MASH / NASHHepatocellular Carcinoma | |
Sugemalimab(Cejemly) | Phase 3 | PD-L1Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
December 2029 (1)
Est. primary completion 2029-12 · NCT05700448 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.